Table 2.

Best-fit parameter values obtained from comparisons of model predictions [Eq. (1)] with data from the HCV genotype 1a infected patients who were given telaprevir alone.

Patient	ρT (day-1)	δ (day-1)	μ (10-6)	εs	εr	β (10-8 mL day-1 virion-1)	ps (virions cell-1 day-1)	r	Infected cells at baseline* (%)	Increase in total hepatocytes (%)
1002	1.91	0.52	2.68	0.99943	0.001	4.30	44.36	0.80	16	32
1018	2.38	0.41	13.91	0.99982	0.036	0.58	131.08	0.70	16	11
3006	2.50	0.50	5.98	0.99548	0.003	11.21	6.60	0.97	11	7
3017	1.21	0.32	1.99	0.99965	0.002	19.41	6.17	0.84	16	32
Average±SD	2.00±0.59	0.44±0.09	6.14±5.46	0.99860±0.00210	0.011±0.017	8.88±8.29	47.05±58.81	0.83±0.11	15±2.5	21±13

^*During data fitting, we assumed that half the maximum number of hepatocytes are not targets of HCV infection (N=T_max/2). With this assumption, about 15% of hepatocytes were infected before treatment, consistent with the experimental results in (25, 26). Using a smaller N, e.g., N=T_max/4, we will have a higher percentage of infected cells at baseline and an unrealistic increase in the total number of hepatocytes after 14-day treatment. Using a larger N, e.g., N=3T_max/4, we could not obtain good fits because of limited replication space for drug-resistant virus.